Larynx preservation and survival trends: Should there be concern?

Head and Neck

Volumn 32, Issue 1, 2010, Pages 14-17

  Forastiere, Arlene A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoradiation; Laryngectomy; Larynx cancer; Larynx preservation; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; HUMAN; HYPOPHARYNX CANCER; LARYNGECTOMY; LARYNX CANCER; NOTE; OROPHARYNX CANCER; PRIORITY JOURNAL; SPEECH; SWALLOWING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; NEOPLASM STAGING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 75149139891     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21295     Document Type: Note

References (11)

1. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116 (Suppl 111):1-13.
2. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2008;101:142-152.
3. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899.
4. Wolf GT, Hong WK, Gross Fisher S, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer (The Department of Veterans Affairs [VA] Laryngeal Cancer Study Group). N Engl J Med 1991;324:1685-1690.
5. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349: 2091-2098.
6. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506.
7. Forastiere AA, Ang KK, Brizel D, et al. Head and neck cancers. J Natl Compr Canc Netw 2008;6:646-695.
8. Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24:3693-3704.
9. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007;133:1270-1276.
10. Olsen K. Reexamining the treatment of advanced laryngeal cancer. Head Neck 2009;31:000-000.
11. Forastiere AA, Maor M, Weber R, et al. Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol 2006;24:284s (abstract).